Somatropin injections are used to replace growth hormone (a natural hormone produced by the body) in adults and children with growth hormone deficiency. Somatropin injections are also used to increase growth in children with certain conditions that affect normal growth and development. Somatropin injection comes as a solution (liquid) in prefilled dosing pens and cartridges and also as a powder in vials and cartridges to be mixed with liquid to be injected subcutaneously (under the skin). When somatropin injections are given to replace growth hormone in adults, it is usually given once a day. Somatropin injections (Serostim) are used to increase body weight and physical endurance in patients with the human immunodeficiency virus (HIV) who have HIV-associated wasting syndrome. Somatropin injections (Zorbtive) are used to treat short bowel syndrome in adults who are receiving additional nutrition or fluids from intravenous (IV) therapy. Somatropin is a human growth hormone (hGH) analog. It works by replacing growth hormones that are normally produced in the body, which may result in increased growth, body weight, and improved absorption of nutrients and fluids from the intestines. When somatropin injection to replace growth hormone or increase growth in children, it is usually given once daily for 3 to 7 days each week. Increasing product launches or product approvals by the regulatory authorities and an increase in the long term effect of growth hormone therapy on children with growth hormone deficiency are expected to fuel the growth of the global somatropin market over the forecast period.

Market Dynamics

Increasing product approval by regulatory authorities and an increase in the long term effect of growth hormone therapy on children with growth hormone deficiency is expected to fuel growth of the global somatropin market over the forecast period. For instance, in January, 2022, Ascendis Pharma A/S, a company that manufactures pharmaceutical products, announced that the European Commission (EC) granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatment of children and adolescents aged 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone (also known as growth hormone deficiency, or GHD). TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body.

Key features of the study:

• This report provides in-depth analysis of the global somatropin market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global somatropin market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Changchun GeneScience Pharmaceutical Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., AnkeBio Co., Ltd, Reliance Life Sciences, JCR Pharmaceuticals Co., Ltd, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd and USV Private Limited
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global somatropin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global somatropin market

Detailed Segmentation:

• Global Somatropin Market, By Dosage Form:
  • Powder
  • Solvent
• Global Somatropin Market, By Application:
  • Growth Hormone Deficiency (GHD)
  • Turner Syndrome
  • Chronic Renal Insufficiency
  • Prader Willi Syndrome
  • Small for Gestational Age
  • SHOX Deficiency
  • Others
• Global Somatropin Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Somatropin Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Novo Nordisk A/S 
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Changchun Gene Science Pharmaceutical Co., Ltd.
  • Sandoz International GmbH
  • Ipsen Pharma
  • LG Chem
  • Merck KGaA
  • Genentech, Inc.
  • Ferring B.V.
  • AnkeBio Co., Ltd
  • Reliance Life Sciences
  • JCR Pharmaceuticals Co., Ltd
  • Zhongshan Sinobioway Hygene Biomedicine Co., Ltd
  • USV Private Limited